Q-omics provides the consensus-scored GTF2A1 profile across patient tissues and cancer cell-line models. GTF2A1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GTF2A1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GTF2A1 RNA expression shows 21,035 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where GTF2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2A1 survival associations across molecular data types. GTF2A1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2A1 RNA expression–survival associations across cancer types. High GTF2A1 expression shows unfavorable associations in ACC and UVM, but favorable associations in SCLC, KIRC, LUSC and THYM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for GTF2A1 RNA expression.
This table summarizes GTF2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2A1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, LIHC and LUSC. The HNSC box plot shows higher GTF2A1 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with GTF2A1 in patient tissues and cancer cell lines. In patient samples, GTF2A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
